Total Payments
$73,260
2024 Payments
$14,901
Companies
5
Transactions
95
Medicare Patients
5,836
Medicare Billing
$544,334
Payment Breakdown by Category
Other$67,875 (92.6%)
Travel$3,412 (4.7%)
Food & Beverage$1,848 (2.5%)
Consulting$125.00 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $67,875 | 47 | 92.6% |
| Travel and Lodging | $3,412 | 21 | 4.7% |
| Food and Beverage | $1,848 | 26 | 2.5% |
| Consulting Fee | $125.00 | 1 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $73,087 | 91 | $0 (2024) |
| Bayer HealthCare Pharmaceuticals Inc. | $125.00 | 1 | $0 (2020) |
| Insmed, Inc. | $19.43 | 1 | $0 (2021) |
| Sunovion Pharmaceuticals Inc. | $15.57 | 1 | $0 (2017) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $12.82 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $14,901 | 18 | AstraZeneca Pharmaceuticals LP ($14,901) |
| 2023 | $18,568 | 20 | AstraZeneca Pharmaceuticals LP ($18,568) |
| 2022 | $24,914 | 30 | AstraZeneca Pharmaceuticals LP ($24,914) |
| 2021 | $6,796 | 10 | AstraZeneca Pharmaceuticals LP ($6,777) |
| 2020 | $2,513 | 6 | AstraZeneca Pharmaceuticals LP ($2,375) |
| 2019 | $5,531 | 9 | AstraZeneca Pharmaceuticals LP ($5,531) |
| 2018 | $21.12 | 1 | AstraZeneca Pharmaceuticals LP ($21.12) |
| 2017 | $15.57 | 1 | Sunovion Pharmaceuticals Inc. ($15.57) |
All Payment Transactions
95 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,350.00 | General |
| Category: Respiratory | ||||||
| 12/09/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,350.00 | General |
| Category: Respiratory | ||||||
| 12/05/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Travel and Lodging | In-kind items and services | $84.56 | General |
| Category: Respiratory | ||||||
| 11/26/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,800.00 | General |
| Category: Respiratory | ||||||
| 11/21/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $118.56 | General |
| Category: Respiratory | ||||||
| 11/21/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Travel and Lodging | In-kind items and services | $69.82 | General |
| Category: Respiratory | ||||||
| 11/20/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $950.00 | General |
| Category: Respiratory | ||||||
| 10/24/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Travel and Lodging | In-kind items and services | $84.56 | General |
| Category: Respiratory | ||||||
| 10/03/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $600.00 | General |
| Category: Respiratory | ||||||
| 09/04/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,400.00 | General |
| Category: Respiratory | ||||||
| 08/29/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $22.77 | General |
| Category: Respiratory | ||||||
| 07/04/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $125.00 | General |
| Category: Respiratory | ||||||
| 07/02/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $250.00 | General |
| Category: Respiratory | ||||||
| 07/02/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $150.00 | General |
| Category: Respiratory | ||||||
| 06/28/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,800.00 | General |
| Category: Respiratory | ||||||
| 06/25/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $90.99 | General |
| Category: Respiratory | ||||||
| 06/25/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Travel and Lodging | In-kind items and services | $54.75 | General |
| Category: Respiratory | ||||||
| 03/05/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $600.00 | General |
| Category: Respiratory | ||||||
| 12/12/2023 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $300.00 | General |
| Category: Respiratory | ||||||
| 10/23/2023 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,400.00 | General |
| Category: Respiratory | ||||||
| 10/17/2023 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $21.47 | General |
| Category: Respiratory | ||||||
| 07/25/2023 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,850.00 | General |
| Category: Respiratory | ||||||
| 07/25/2023 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,400.00 | General |
| Category: Respiratory | ||||||
| 07/19/2023 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $117.94 | General |
| Category: Respiratory | ||||||
| 07/11/2023 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $600.00 | General |
| Category: Respiratory | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 16 | 1,483 | 2,067 | $564,686 | $143,251 |
| 2022 | 17 | 1,502 | 1,898 | $536,246 | $133,983 |
| 2021 | 18 | 1,416 | 1,890 | $482,679 | $144,689 |
| 2020 | 23 | 1,435 | 1,919 | $455,290 | $122,412 |
Total Patients
5,836
Total Services
7,774
Medicare Billing
$544,334
Procedure Codes
76
All Medicare Procedures & Services
76 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 346 | 507 | $185,616 | $47,453 | 25.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 198 | 349 | $179,714 | $45,919 | 25.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 66 | 66 | $41,638 | $10,366 | 24.9% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 23 | 87 | $28,289 | $8,117 | 28.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 47 | 47 | $22,460 | $5,354 | 23.8% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 47 | 56 | $20,436 | $5,027 | 24.6% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2023 | 117 | 118 | $19,612 | $4,860 | 24.8% |
| 94726 | Test to determine lung volumes using sensors | Office | 2023 | 111 | 112 | $17,632 | $4,569 | 25.9% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2023 | 118 | 118 | $18,809 | $3,345 | 17.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 22 | 23 | $11,860 | $3,128 | 26.4% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2023 | 102 | 118 | $7,851 | $1,976 | 25.2% |
| 94618 | Test for exercise-induced lung stress | Office | 2023 | 51 | 57 | $5,495 | $1,419 | 25.8% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2023 | 13 | 13 | $2,659 | $979.97 | 36.9% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 14 | 14 | $1,216 | $429.38 | 35.3% |
| 85018 | Blood count, hemoglobin | Office | 2023 | 124 | 131 | $1,055 | $301.96 | 28.6% |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | Office | 2023 | 84 | 251 | $344.00 | $6.72 | 2.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 388 | 561 | $204,388 | $49,764 | 24.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 166 | 293 | $150,282 | $40,226 | 26.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 49 | 49 | $30,736 | $7,760 | 25.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 61 | 61 | $28,916 | $6,501 | 22.5% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 49 | 72 | $26,191 | $6,435 | 24.6% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2022 | 113 | 113 | $18,984 | $4,844 | 25.5% |
| 94726 | Test to determine lung volumes using sensors | Office | 2022 | 104 | 104 | $16,228 | $4,286 | 26.4% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2022 | 114 | 114 | $18,012 | $3,302 | 18.3% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2022 | 162 | 183 | $11,980 | $3,051 | 25.5% |
About Dr. Benjamin Sy, M.D
Dr. Benjamin Sy, M.D is a Critical Care Medicine healthcare provider based in Bremerton, Washington. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/17/2006. The National Provider Identifier (NPI) number assigned to this provider is 1427075183.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Benjamin Sy, M.D has received a total of $73,260 in payments from pharmaceutical and medical device companies, with $14,901 received in 2024. These payments were reported across 95 transactions from 5 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($67,875).
As a Medicare-enrolled provider, Sy has provided services to 5,836 Medicare beneficiaries, totaling 7,774 services with total Medicare billing of $544,334. Data is available for 4 years (2020–2023), covering 76 distinct procedure/service records.
Ad
Practice Information
- Specialty Critical Care Medicine
- Other Specialties Pulmonary Disease, Internal Medicine
- Location Bremerton, WA
- Active Since 07/17/2006
- Last Updated 12/14/2010
- Taxonomy Code 207RC0200X
- Entity Type Individual
- NPI Number 1427075183
Products in Payments
- FASENRA (Biological) $39,979
- BREZTRI (Drug) $17,073
- TEZSPIRE (Biological) $8,108
- FASENRA (Drug) $7,927
- Adempas (Drug) $125.00
- Arikayce (Drug) $19.43
- BROVANA (Drug) $15.57
- OFEV (Drug) $12.82
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.